BCG046 / Biocytogen - LARVOL DELTA

BCG046, a CDCP1 ADC that targets CTF, has demonstrated potent in vitro and in vivo efficacy (AACR 2026) - "When conjugated to vcMMAE, Ab.168-vcMMAE demonstrated superior or comparable efficacy to benchmark ADCs in NSCLC and colorectal patient-derived xenograft (PDX) models.Conclusion These findings underscore the therapeutic potential of Ab.168 in developing an ADC as a promising strategy for treating colorectal cancer and other solid tumors characterized by CDCP1 expression. Further preclinical studies are underway."

ADC • Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDCP1